According to
the new market research report "Humanized
Mouse and Rat Model Market by Type
(Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience,
Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical
& Biotechnology Companies, CRO)) - Global Forecast",
published by MarketsandMarkets™, The humanized rat models market is expected to reach
USD 8.9 Million, at a CAGR of 8.4% during the forecast period. The humanized
mouse models market is projected to reach USD 128.9 Million, at a CAGR of 9.9%
during the forecast period.
Growth in this market can primarily be attributed to factors
such as the growing demand of personalized medicine, continuous support in the
form of investments and grants from the government and private sectors,
increasing number of R&D activities in pharmaceutical and biotechnology
companies, and the increasing number of research activities involving humanized
models. Increasing production of monoclonal antibodies and rising demand for
humanized rat models are expected to provide a wide range of growth
opportunities for players in the market.
The oncology segment commanded the largest share of the
humanized mouse models market.
By application, the humanized mouse models market is
categorized into oncology, immunology and infectious diseases, neuroscience,
hematopoiesis, toxicology, and other applications. Of all these application
segments, oncology accounted for the largest share of the humanized mouse
models market in 2017. The increasing research activities and growing funding
from various governments to carry out research studies on cancer are the major
factors driving the growth of this segment.
94 - Tables
42 - Figures
189 - Pages
Cell-based humanized mouse models to grow at the highest
CAGR during the forecast period
By type, the humanized mouse models market is categorized
into genetic and cell-based humanized mouse models. The cell-based humanized
mouse models segment is expected to grow at the highest CAGR during the study
period (2017–2022). The high growth of this segment can be attributed to the
growing applications of cell-based humanized mouse models.
The cell-based humanized mouse models segment is further
categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34
models segment commanded the largest share of the cell-based humanized mouse
models market and is expected to grow at the highest CAGR during the forecast
period.
Contract Research Organizations (CROs) to dominate the
humanized mouse models market during the forecast period
By end user, the humanized mouse models market is
categorized into pharmaceutical & biotechnology companies, contract
research organizations (CRO), and academic & research institutions. The
contract research organizations (CROs) segment is projected to grow at the
highest CAGR during the forecast period. Growth in this segment is largely due
to the increasing number of pharmaceutical companies outsourcing their
preclinical studies to contract research organizations (CROs).
North America dominated the market in 2017
North America dominated the global humanized mouse models
market in 2017. Growth in this regional segment can be attributed to the
increasing monoclonal antibody production, preclinical activities by CROs and
pharmaceutical R&D, continued and responsible use of animals ensured by
animal care organizations, growing biomedical research in the US along with
government support for the development of protein drugs, and growing stem cell
research in Canada.
The major market players in the humanized mouse models
market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US),
Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River
Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar
Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS
S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and
Champions Oncology, Inc. (US). The major players in the humanized rat models
market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris
Corporation (US).
No comments:
Post a Comment